Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Fig. 1

a Proportion of patients achieving Psoriatic Arthritis Disease Activity Score (PASDAS) remission, LDA, MoDA and HDA at weeks 16, 52 and 104 in overall population. Data were reported using mutually exclusive categories at group level and as observed analysis. LDA: 1.9 < PASDAS score < 3.2; remission: PASDAS score ≤ 1.9. Secukinumab 300 and 150 mg data are reported (approved doses). n = number of patients in the treatment group with evaluation. b Shift analysis of PASDAS disease activity states from week 16 to week 52 or 104. Data were reported using mutually exclusive categories at group level and as observed analysis. n = number of patients in each PASDAS state at week 16; N = total number of patients with non-missing PASDAS scores at week 16 and weeks 52/104. HDA High disease activity, LDA Low disease activity, MoDA Moderate disease activity

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us